The first time I noticed@Injective , was at a certain hackathon at the end of last year. At that time, it had just teamed up with Polygon to conduct a technical research project aimed at enabling seamless circulation of Polygon's assets on Injective. Just think about it, Polygon's low gas fees combined with Injective's lightning TPS (tens of thousands of transactions per second) directly pushed aside the fragmentation issue in the cross-chain market. What was the result? Not only a technical integration, but users began trading Polygon's MATIC derivatives on Injective, and liquidity surged in like a burst pipe. This isn't some earth-shattering press conference, but a solid ecological expansion that transformed Injective from a DeFi tool into a multi-chain hub.

Fast forward to 2025,#injective the collaboration network is becoming increasingly dense. Take Aethir for example, this decentralized GPU cloud provider partnered with Injective in March, injecting enterprise-level AI and gaming resources directly onto the blockchain. When you trade on Injective's DEX, you can conveniently call Aethir's GPU to run an AI model and predict the trend of the next perpetual contract? This is not science fiction. It unlocks AI-driven dApps, transforming DeFi from mere digital asset trading into a brainy financial laboratory. Aethir's addition not only fills Injective's computing power gap but also attracts a wave of game developers. As a result, Injective's on-chain game trading volume doubled in the second half of the year, proving that collaboration is not about piling up functions, but about sparking new gameplay.

Looking at the RWA (real-world assets) line, Injective's ambition is even greater. The partnership with BitGo is a typical example: BitGo, as a giant in digital asset custody, now supports the integration of INJ tokens and is promoting KAVA proposal 165 to incentivize the adoption of USDt on Injective. What does this mean? Traditional financial institutions can more confidently put RWA such as U.S. Treasuries and gold on-chain, making perpetual contracts or options trading on Injective. Don't underestimate this. At the end of last year, Injective's RWA perpetual contract trading volume broke the $1 billion mark, covering stocks, foreign exchange, commodities, and indices. BitGo's endorsement acts like a safety net, allowing both retail and institutional investors to place heavy bets. Compared to other chains' RWA projects, Injective's uniqueness lies in its order book mechanism, which avoids the slippage issues of AMMs, making large transactions as smooth as on the Chicago Exchange.

Of course, Injective's collaborations go beyond just the core of DeFi. The marriage with Elrond is even more interesting: Elrond's high scalability was originally prepared for enterprise-level dApps, and now, through Injective, it opens new markets and introduces decentralized derivatives. Elrond users can hedge risks directly on Injective, while Injective traders gain access to a basket of assets from the Elrond ecosystem. These two projects emphasize speed and financial depth, and together they directly challenge Ethereum's dominance in derivatives. Similarly, the interoperability integration with Solana allows Injective users to trade Solana's meme coins or NFTs across chains, reducing the pain points of bridging. In the first half of 2025, this cross-chain traffic accounted for 30% of Injective's total, showing that collaboration is not just icing on the cake but the lifeblood of the ecosystem.

Don't think that Injective only loves to play with on-chain projects. It also targets players in the real world. For example, joining the Blockchain Association, this U.S. pro-crypto lobbying group, allows Injective's voice to reach Washington directly. Just think about it: in the high uncertainty of policies in 2025, being able to push for blockchain-friendly regulations alongside industry leaders is not just PR, but a strategic layout. The result? Heavyweights like FalconX and MK Media Group have joined Injective's list of institutional validators, with the former being the world's largest crypto staking brokerage and the latter being a leading financial media outlet in South Korea. This move not only raised the TVL (Total Value Locked) but also helped Injective establish a foothold in the Asian market. South Korean users can now intuitively understand on-chain RWA opportunities through local media.

$INJ

Injective's MultiVM mainnet (supporting EVM and WASM) is a highlight, but during early integration, there were always minor compatibility bugs, and the collaboration with Google Cloud helped a lot. They not only sponsored hackathons but also provided cloud infrastructure to help developers avoid detours while testing EVM. Now, 40% of the dApp fees are directly returned to developers, creating a self-circulating engine that attracts lending protocols like Hydro, Morpho, and Neptune. Hydro's money market and Morpho's P2P optimized lending rely on Injective's low fees and instant settlement. In Q3 of last year, Injective's lending TVL increased by 150%, thanks to the collective efforts of these partners.

Injective's collaboration roadmap looks like an ever-expanding map. The upcoming iBuild platform will make AI no-code development more accessible, and the integration with io.net's GPU directly targets DeFAI (Decentralized Finance + AI). Additionally, with Pyth Network putting U.S. GDP data on-chain, Injective's oracle ecosystem can now support the entire link from macroeconomics to micro-trading. What about risks? Regulatory uncertainty and cross-chain security are always present, but Injective's MEV-resistant order book and Tendermint consensus keep it steady in volatile markets.